Trials / Withdrawn
WithdrawnNCT02166229
Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the ability of divalproex sodium, a histone deacetylase inhibitor, to improve the digital manifestations of scleroderma including digital edema, calcinosis cutis, digital ulcers, and joint contractures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Divalproex sodium |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2014-06-18
- Last updated
- 2016-08-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02166229. Inclusion in this directory is not an endorsement.